Asian stocks opened higher on Wednesday after the S&P 500 Index climbed to a fresh record, supported by data showing the US economy expanded at its fastest pace in two years.

U.S. stocks ended Tuesday's session at fresh record highs after data showed stronger-than-expected economic growth during the summer months.

Here's a table showing how US stocks performed on Tuesday:

Source: Equitymaster

At present, the BSE Sensex is trading 131 points higher, and the NSE Nifty is trading 40 points higher.

Trent, NTPC, and Bajaj Finance are among the top gainers today.

Infosys, HUL, and Tech Mahindra, on the other hand, are among the top losers today.

The BSE Midcap index is trading 0.2% higher, and the BSE Smallcap index is trading 0.4% higher.

Barring the FMCG and IT sector, all other sectoral indices are trading positively today, with stocks in realty and metal witnessing buying.

The rupee is trading at Rs 89.7 against the US dollar.
 

APSEZ Expands Globally with NQXT Acquisition

Adani Ports and Special Economic Zone (APSEZ) have completed the acquisition of 100% stake in NQXT (North Queensland Export Terminal), Australia. The deal was completed by issuing 143.8 million equity shares (face value Rs 2 each) to the seller, Carmichael Rail and Port Singapore Holdings, through a preferential allotment.

After this acquisition, APSEZ has upgraded its FY26 EBITDA guidance to Rs 223.5-233.5 bn, compared to the earlier estimate of Rs 210-220 bn.The company has also increased its cargo volume guidance to 545-555 million metric tonnes (MMT) from 505-515 MMT.

NQXT is described as a high-growth, cash-generating asset, mainly supported by long-term take-or-pay contracts, which ensure stable revenues. In the last financial year, NQXT had a contracted capacity of 40 MTPA and generated an EBITDA of AUD 228 million, which is approximately Rs12-13 bn.

On a pro-forma basis, NQXT contributes around 6% of APSEZ's FY25 revenue and 7% of its EBITDA, strengthening APSEZ's global portfolio and earnings visibility.
 

Aurobindo Pharma Expands Via JV Stake Acquisition

Aurobindo Pharma has announced that it will buy an additional 20% stake in its China-based joint venture, Luoxin Aurovitas Pharma, for USD 5.12 million, which is around Rs 0.43 bn.

The transaction will be carried out through Helix Healthcare BV, a wholly owned subsidiary of Aurobindo Pharma. Helix has signed a binding agreement with Shandong Luoxin Pharmaceutical Group, the joint venture partner.

Currently, Luoxin Aurovitas is a 30:70 joint venture, with Helix holding 30% and Shandong Luoxin holding 70%.

The purchase of an additional 20% stake is expected to be completed within the next three months. After this, Aurobindo Pharma will also have the option to acquire the remaining 50% stake by December 2029 for USD 18.86 million, or about Rs 1.56 bn, subject to agreed terms and conditions.

This move will allow Aurobindo Pharma to gradually increase control over its China operations.
 

Ola Electric Mobility Approves Third Funding Tranche

Shares of Ola Electric Mobility are likely to be in focus after its subsidiary, Ola Electric Technologies Private Limited (OET), approved a fresh funding infusion into another group company, Ola Cell Technologies, at its board meeting held on 23 December 2025.

Following shareholder approval to revise the use of IPO proceeds, OET cleared the third tranche of funding worth Rs 1 bn for Ola Cell Technologies. The funding will be made through a private placement of 10 crore optionally convertible redeemable preference shares.

Each preference share has a face value of Rs 10, taking the total issue size to Rs 1 bn. Ola Cell Technologies is a wholly owned subsidiary of Ola Electric Mobility and a fellow subsidiary of Ola Electric Technologies

The company disclosed the approval in a regulatory filing stating that the shares issued are non-cumulative, non-participating, Series A optionally convertible redeemable preference shares.

More By This Author: